Early national and center-level changes to kidney transplantation in the United States during the COVID-19 epidemic
Brian J. Boyarsky(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Indraneel M. Massie(Emory University), Amber Kernodle(Brigham and Women's Hospital), Jon J. Snyder(Hennepin Healthcare Research Institute), Robin K. Avery(Johns Hopkins University), Kyle R. Jackson(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Ryutaro Hirose(University of Washington), Dorry L. Segev(New York University), Christine M. Durand(University of Maryland, Baltimore)
Cited by 75
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States
|American Journal of Kidney Diseases|2021|727